The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

Abstract Background Lung cancer patients with an activating mutation in the EGFR (epidermal growth factor receptor) can develop resistance to erlotinib treatment, which is often mediated by the T790M resistance mutation in EGFR. The difficulties in obtaining biopsies at progression make it challengi...

Full description

Bibliographic Details
Main Authors: Christina Demuth, Anne Tranberg Madsen, Britta Weber, Lin Wu, Peter Meldgaard, Boe Sandahl Sorensen
Format: Article
Language:English
Published: BMC 2018-02-01
Series:BMC Cancer
Subjects:
Carcinoma
Non-small cell lung
Receptor
Epidermal growth factor
Erlotinib
Drug resistance
Online Access:http://link.springer.com/article/10.1186/s12885-018-4108-0

Internet

http://link.springer.com/article/10.1186/s12885-018-4108-0

Similar Items